在CDK4/6抑制剂治疗后进展的激素受体阳性/HER2阴性转移性乳腺癌中,内分泌治疗联合或不联合瑞博西利:MAINTAIN随机II期试验
MAINTAIN试验入组119例激素受体阳性/HER2阴性转移性乳腺癌患者,均在既往内分泌治疗联合CDK4/6抑制剂期间进展,随机分配至更换内分泌治疗(氟维司群或依西美坦)联合瑞博西利或安慰剂。瑞博西利组中位无进展生存期5.29个月,安慰剂组2.76个月,HR 0.57(95%CI 0.39-0.85),P=0.006,差异有统计学意义。
要点
- 更换内分泌治疗联合瑞博西利较安慰剂显著改善无进展生存期,HR 0.57(95%CI 0.39-0.85),P=0.006。
- 瑞博西利组中位无进展生存期5.29个月,安慰剂组2.76个月。
- 6个月和12个月无进展生存率:瑞博西利组41.2%和24.6%,安慰剂组23.9%和7.4%。
核心结论
- 在既往CDK4/6抑制剂和不同内分泌治疗后进展的激素受体阳性/HER2阴性转移性乳腺癌患者中,更换内分泌治疗并接受瑞博西利较安慰剂显著改善无进展生存期。
研究设计与样本
- 研究者发起的II期双盲安慰剂对照随机试验,1:1随机分配至瑞博西利或安慰剂。
- 入组119例激素受体阳性/HER2阴性转移性乳腺癌患者,均在既往内分泌治疗联合CDK4/6抑制剂期间进展,随机前更换内分泌治疗为氟维司群或依西美坦。
- 主要终点为无进展生存期,定义为随机分配至疾病进展或死亡的时间。
- 假设安慰剂组中位无进展生存期3.8个月,以单侧log-rank检验、显著性水平2.5%、120例随机分配患者,有80%把握度检测风险比0.58(对应瑞博西利组中位无进展生存期至少6.5个月)。
主要发现
- 119例随机分配患者中,103例(86.5%)既往接受过哌柏西利,14例(11.7%)既往接受过瑞博西利。
- 更换内分泌治疗联合瑞博西利组中位无进展生存期5.29个月(95%CI 3.02-8.12个月),安慰剂组2.76个月(95%CI 2.66-3.25个月),HR 0.57(95%CI 0.39-0.85),P=0.006。
- 6个月和12个月无进展生存率:瑞博西利组分别为41.2%和24.6%,安慰剂组分别为23.9%和7.4%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Although preclinical and clinical data demonstrate a benefit in changing ET and continuing a CDK4/6i at progression, no randomized prospective trials have evaluated this approach. METHODS: In this investigator-initiated, phase II, double-blind placebo-controlled trial in patients with HR+/HER2- MBC whose cancer progressed during ET and CDK4/6i, participants switched ET (fulvestrant or exemestane) from ET used pre-random assignment and randomly assigned 1:1 to the CDK4/6i ribociclib versus placebo. PFS was the primary end point, defined as time from random assignment to disease progression or death. Assuming a median PFS of 3.8 months with placebo, we had 80% power to detect a hazard ratio (HR) of 0.58 (corresponding to a median PFS of at least 6.5 months with ribociclib) with 120 patients randomly assigned using a one-sided log-rank test and significance level set at 2.5%. RESULTS: Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006. At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo. CONCLUSION: In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2- MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.
引用
- Kalinsky K, Accordino MK, Chiuzan C, et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023. PMID: 37207300. doi:10.1200/JCO.22.02392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。